CJC-1295 (No DAC)

CJC-1295 is a modified peptide derived from the original compound CJC-1295-20, which is widely studied for its potential neuroendocrine modulation effects. As a non-dodecanoyl-acylated (No DAC) variant, this peptide maintains its structural integrity while offering a distinct pharmacokinetic profile compared to its DAC-modified counterpart.

Research Context

CJC-1295 has been extensively researched in preclinical models for its role in modulating pituitary hormones, particularly growth hormone-releasing hormone (GHRH) and its downstream signaling pathways. The peptide was initially developed as a potential therapeutic agent for growth hormone deficiency, though its primary application in academic and industrial research settings remains focused on understanding neuroendocrine regulation, neuroprotection, and potential regenerative mechanisms.

Research Overview

The non-DAC form of CJC-1295 was introduced to address concerns regarding rapid clearance and metabolic breakdown observed with the DAC variant. While both forms share similar binding affinities to the GHRH receptor, the absence of dodecanoyl acetylation in this peptide variant may influence its tissue distribution and half-life, enabling targeted experimentation in controlled in vivo and in vitro models. Key studies have explored its effects on pituitary function, neuroendocrine feedback loops, and potential neuroprotective roles in aging and neurodegenerative disease models.

Key Research Focus Areas

• Neuroendocrine Regulation: Investigation of peptide-induced changes in pituitary hormone secretion, particularly growth hormone and prolactin release, in both rodent and primate models.
• Neuroprotection and Aging: Exploration of CJC-1295’s potential role in modulating neuroinflammation, synaptic plasticity, and cognitive function in aging and neurodegenerative conditions.
• Regenerative Biology: Assessment of peptide-induced effects on tissue regeneration, including muscle hypertrophy, wound healing, and potential impacts on organ function in preclinical settings.
• Pharmacokinetic Studies: Comparative analysis of CJC-1295 (No DAC) versus its DAC-modified counterpart, including serum half-life, receptor binding kinetics, and tissue-specific uptake profiles.
• Thermal Regulation: Preliminary observations in rodent models on peptide-induced thermoregulatory effects, particularly in relation to hypothalamic-pituitary-adrenal (HPA) axis modulation.

Important Safety and Compliance Note

CJC-1295 (No DAC) is provided solely for research purposes and is not intended for human or animal consumption. The safety, efficacy, and appropriate use of this peptide have not been evaluated in clinical trials. Users must adhere to all applicable institutional, national, and international regulations governing the handling, storage, and disposal of research chemicals. Only qualified researchers with appropriate authorization and safety protocols may utilize this compound. Any experimentation must comply with all regulatory requirements, including but not limited to those outlined by the Research Chemical Supply Association (RSCA) and relevant local or national legislation.

For Research Use Only. Not for Human or Animal Consumption.